실시간 정량적 중합효소연쇄반응을 이용한 Abbott RealTime HBVQuantification Kit의 성능평가
Performance Evaluation of Abbott RealTime HBV Quantification Kit for HBV Viral Load byReal-Time PCR
1
조회
0
다운로드
1
인용
0
참고문헌
초록
Abstract
Background : Hepatitis B virus (HBV) DNA quantification is necessary for starting and monitoring of antiviral therapy in patients with chronic hepatitis B. This study was intended to assess the clinical performance of Abbott RealTime HBV Quantification kit (Abbott Laboratories, USA). Methods : The performance was evaluated in terms of precision, linearity, detection sensitivity, cross-reactivity, and carry-over. A correlation with the Real-Q HBV Quantification kit (BioSewoom Inc., Korea) was also examined using serum samples from 64 patients diagnosed with chronic hepatitis B and underwent lamivudine therapy in Asan Medical Center. We verified the trueness of the system by comparing the outputs with the assigned values of the BBI panel (BBI Diagnostics, USA). Results : Within-run and between-run coefficients of variation (CV) were 3.56-4.71% and 3.03- 4.98%, respectively. Linearity was manifested ranging from 53 to 109 copies/mL and the detection sensitivity was verified to be 51 copies/mL. None of hepatitis C virus showed cross-reactivity. No cross-contamination occurred when negative and positive samples were alternatively placed in a row. It showed a good correlation with the Real-Q HBV (r2=0.9609) and the test results for the BBI panel were also well agreed to the assigned values (r2=0.9933). Conclusions : The performance of Abbott RealTime HBV Quantification kit was excellent; thus, it should be widely used in starting and monitoring of antiviral therapy in Korean patients with chronic hepatitis B. (Korean J Lab Med 2008;28:144-50)
참고문헌 (24)
- Di Bisceglie A, "Telbivudine globe trial: maximal early HBV suppression is predictive of optimal two-year efficacy in nucleoside-treated hepatitis B patients", Hepatology, 44(S1), pp.230~231 (2006)
- Hadziyannis SJ, "Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years", Gastroenterology, 131, pp.1743~1751 (2006)
- Yuen MF, "Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy", Hepatology, 34, pp.785~791 (2001)
- Chen CJ, "Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level", JAMA, 295, pp.65~73 (2006)
- 김선희, "진단유전학분과 신빙도조사 결과보고(2006)", 임상검사와정도관리, 29(1), pp.153~174 (2006), 대한임상검사정도관리협회
- Konnick EQ, "Evaluation of the COBAS amplicor HBV monitor assay and comparison with the ultrasensitive HBV hybrid capture 2 assay for quantification of hepatitis B virus DNA", J Clin Microbiol, 43, pp.596~603 (2005)
- Pawlotsky JM, "Routine detection and quantification of hepatitis B virus DNA in clinical laboratories: performance of three commercial assays", J Virol Methods, 85, pp.11~21 (2000)
- Lee HC, "Quantitative polymerase chain reaction assay for serum hepatitis B virus DNA as a predictive factor for post-treatment relapse after lamivudine induced hepatitis B e antigen loss or seroconversion", Gut, 52, pp.1179~1183 (2003)
- Lok AS, "Chronic hepatitis B", Hepatology, 45, pp.507~539 (2007)
- Mackay IM, "Real-time PCR in the microbiology laboratory", Clin Microbiol Infect, 10, pp.190~212 (2004)
- Holland PM, "Detection of specific polymerase chain reaction product by utilizing the 5’----3’ exonuclease activity of Thermus aquaticus DNA polymerase", Proc Natl Acad Sci USA, 88, pp.7276~7280 (1991)
- Lee LG, "Allelic discrimination by nick-translation PCR with fluorogenic probes", Nucleic Acids Res, 21, pp.3761~6766 (1993)
- Valasek MA, "The power of real-time PCR", Adv Physiol Educ, 29, pp.151~159 (2005)
- 황상현1, "실시간 정량적 중합효소연쇄반응을 이용한 Real-Q HBV Quantification Kit의성능평가", 대한진단검사의학회지, 26(6), pp.442~448 (2006), 대한진단검사의학회
- Dienstag JL, "Lamivudine as initial treatment for chronic hepatitis B in the United States", N Engl J Med, 341, pp.1256~1263 (1999)
- Lai CL, "A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group", N Engl J Med, 339, pp.61~68 (1998)
- Schalm SW, "Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial", Gut, 46, pp.562~568 (2000)
- Chang TT, "Four years of lamivudine treatment in Chinese patients with chronic hepatitis B", J Gastroenterol Hepatol, 19, pp.1276~1282 (2004)
- Lok AS, "Longterm safety of lamivudine treatment in patients with chronic hepatitis B", Gastroenterology, 125, pp.1714~1722 (2003)
- Fung SK, "Virologic response and resistance to adefovir in patients with chronic hepatitis B", J Hepatol, 44, pp.283~290 (2006)
- Lee YS, "Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy", Hepatology, 43, pp.1385~1391 (2006)
- Klein D, "Quantification using real-time PCR technology: applications and limitations", Trends Mol Med, 8, pp.257~260 (2002)
- Laperche S, "Expertise of laboratories in viral load quantification, genotyping, and precore mutant determination for hepatitis B virus in a multicenter study", J Clin Microbiol, 44, pp.3600~3607 (2006)
- Weiss J, "Real time TaqMan PCR detection and quantitation of HBV genotypes A-G with the use of an internal quantitation standard", J Clin Virol, 30, pp.86~93 (2004)